Bacillus Calmette-Guerin (BCG) immunotherapy for bladder cancer: Current understanding and perspectives on engineered BCG vaccine

Cancer Science

Volumn 104, Issue 1, 2013, Pages 22-27

  Kawai, Koji ^a   Miyazaki, Jun ^a   Joraku, Akira ^a   Nishiyama, Hiroyuki ^a   Akaza, Hideyuki ^b  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BCG VACCINE; LIPOSOME;

BACTERIAL CELL WALL; BCG VACCINATION; BIOENGINEERING; BLADDER CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CYSTECTOMY; DNA POLYMORPHISM; HUMAN; IMMUNE RESPONSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; URINARY FREQUENCY;

ADMINISTRATION, INTRAVESICAL; BCG VACCINE; HUMANS; IMMUNOTHERAPY; LIPOSOMES; MYCOBACTERIUM BOVIS; URINARY BLADDER NEOPLASMS; UROTHELIUM; VACCINES, SYNTHETIC;

EID: 84872267596     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12075     Document Type: Review

References (62)

1. Herr HW, Morales A. History of bacillus Calmette-Guerin and bladder cancer: an immunotherapy success story. J Urol 2008; 179: 53-6.
2. Morales A, Eidinger D, Bruce AW. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol 1976; 116: 180-3.
3. Kirkali Z, Chan T, Manoharan M et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 2005; 66: 4-34.
4. Babjuk M, Oosterlinck W, Sylvester R et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol 2011; 59: 997-1008.
5. Witjes JA. Bladder carcinoma in situ in 2003: state of the art. Eur Urol 2004; 45: 142-6.
6. Weizer AZ, Tallman C, Montgomery JS. Long-term outcomes of intravesical therapy for non-muscle invasive bladder cancer. World J Urol 2011; 29: 59-71.
7. Akaza H, Hinotsu S, Aso Y, Kakizoe T, Koiso K. Bacillus Calmette-Guérin treatment of existing papillary bladder cancer and carcinoma in situ of the bladder. Four-year results. The Bladder Cancer BCG Study Group. Cancer 1995 (Jan 15); 75: 552-9.
8. Akaza H, Koiso K, Ozono S et al. A clinical study of PMCJ-9 (Bacillus Calmette-Guérin Connaught strain) treatment of superficial bladder cancer and carcinoma in situ of the bladder. Jpn J Clin Oncol 2003; 33: 382-90.
9. Brausi M, Witjes JA, Lamm D et al. A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group. J Urol 2011; 186: 2158-67.
10. Sylvester RJ. Bacillus Calmette-Guérin treatment of non-muscle invasive bladder cancer. Int J Urol 2011; 18: 113-20.
11. Lamm DL, Blumenstein BA, Crissman JD et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 2000; 163: 1124-9.
12. Hinotsu S, Akaza H, Naito S et al. Maintenance therapy with bacillus Calmette-Guérin Connaught strain clearly prolongs recurrence-free survival following transurethral resection of bladder tumour for non-muscle-invasive bladder cancer. BJU Int 2011; 108: 187-95.
13. Sylvester RJ, van der Meijden AP, Witjes JA, Kurth K. Bacillus Calmette-Guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J Urol 2005; 174: 86-91.
14. Malmström PU, Sylvester RJ, Crawford DE et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. Eur Urol 2009; 56: 247-56.
15. Smith JA Jr, Labasky RF, Cockett AT, Fracchia JA, Montie JE, Rowland RG. Bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1 and TIS). The American Urological Association. J Urol 1999; 162: 1697-701.
16. Rischmann P, Desgrandchamps F, Malavaud B, Chopin DK. BCG intravesical instillations: recommendations for side-effects management. Eur Urol 2000; 37: 33-6.
17. Gonzalez OY, Musher DM, Brar I et al. Spectrum of bacille Calmette-Guérin (BCG) infection after intravesical BCG immunotherapy. Clin Infect Dis 2003; 36: 140-8.
18. Koya MP, Simon MA, Soloway MS. Complications of intravesical therapy for urothelial cancer of the bladder. J Urol 2006; 175: 2004-10.
19. Akaza H, Iwasaki A, Ohtani M et al. Expression of antitumor response. Role of attachment and viability of bacillus Calmette-Guérin to bladder cancer cells. Cancer 1993; 72: 558-63.
20. Poggi MM, Johnstone PA, Conner RJ. Glycosaminoglycan content of human bladders. A method of analysis using cold-cup biopsies. Urol Oncol 2000; 5: 234-7.
21. Kavoussi LR, Brown EJ, Ritchey JK, Ratliff TL. Fibronectin-mediated Calmette-Guerin bacillus attachment to murine bladder mucosa. Requirement for the expression of an antitumor response. J Clin Invest 1990; 85: 62-7.
22. Saban MR, Simpson C, Davis C et al. Discriminators of mouse bladder response to intravesical Bacillus Calmette-Guerin (BCG). BMC Immunol 2007; 8: 6.
23. Kuroda K, Brown EJ, Telle WB, Russell DG, Ratliff TL. Characterization of the internalization of bacillus Calmette-Guerin by human bladder tumor cells. J Clin Invest 1993; 91: 69-76.
24. Bevers RF, de Boer EC, Kurth KH, Schamhart DH. BCG-induced interleukin-6 upregulation and BCG internalization in well and poorly differentiated human bladder cancer cell lines. Eur Cytokine Netw 1998; 9: 181-6.
25. Maksymowych WP, Kane KP. Bacterial modulation of antigen processing and presentation. Microbes Infect 2000; 2: 199-211.
26. Ikeda N, Toida I, Iwasaki A, Kawai K, Akaza H. Surface antigen expression on bladder tumor cells induced by bacillus Calmette-Guérin (BCG): a role of BCG internalization into tumor cells. Int J Urol 2002; 9: 29-35.
27. Lattime EC, Gomella LG, McCue PA. Murine bladder carcinoma cells present antigen to BCG-specific CD4+ T-cells. Cancer Res 1992; 52: 4286-90.
28. Durek C, Richter E, Basteck A et al. The fate of bacillus Calmette-Guerin after intravesical instillation. J Urol 2001; 165: 1765-8.
29. Prescott S, James K, Hargreave TB, Chisholm GD, Smyth JF. Intravesical Evans strain BCG therapy: quantitative immunohistochemical analysis of the immune response within the bladder wall. J Urol 1992; 147: 1636-42.
30. Prescott S, James K, Hargreave TB, Chisholm GD, Smyth JF. Radio-immunoassay detection of interferon-gamma in urine after intravesical Evans BCG therapy. J Urol 1990; 144: 1248-51.
31. Nadler R, Luo Y, Zhao W et al. Interleukin 10 induced augmentation of delayed-type hypersensitivity (DTH) enhances Mycobacterium bovis bacillus Calmette-Guérin (BCG) mediated antitumour activity. Clin Exp Immunol 2003; 131: 206-16.
32. De Boer EC, De Jong WH, Steerenberg PA et al. Induction of urinary interleukin-1 (IL-1), IL-2, IL-6, and tumour necrosis factor during intravesical immunotherapy with bacillus Calmette-Guérin in superficial bladder cancer. Cancer Immunol Immunother 1992; 34: 306-12.
33. de Boer EC, Somogyi L, de Ruiter GJ, de Reijke TM, Kurth KH, Schamhart DH. Role of interleukin-8 in onset of the immune response in intravesical BCG therapy for superficial bladder cancer. Urol Res 1997; 25: 31-4.
34. Miyazaki J, Kawai K, Oikawa T et al. Uroepithelial cells can directly respond to Mycobacterium bovis bacillus Calmette-Guérin through Toll-like receptor signalling. BJU Int 2006; 97: 860-4.
35. Gopal R, Lin Y, Obermajer N et al. IL-23-dependent IL-17 drives Th1-cell responses following Mycobacterium bovis BCG vaccination. Eur J Immunol 2012; 42: 364-73.
36. Takeuchi A, Dejima T, Yamada H et al. IL-17 production by γδ T cells is important for the antitumor effect of Mycobacterium bovis bacillus Calmette-Guérin treatment against bladder cancer. Eur J Immunol 2011; 41: 246-51.
37. Ratliff TL, Gillen D, Catalona WJ. Requirement of a thymus dependent immune response for BCG-mediated antitumor activity. J Urol 1987; 137: 155-8.
38. Brandau S, Riemensberger J, Jacobsen M et al. NK cells are essential for effective BCG immunotherapy. Int J Cancer 2001; 92: 697-702.
39. Saint F, Patard JJ, Irani J et al. Leukocyturia as a predictor of tolerance and efficacy of intravesical BCG maintenance therapy for superficial bladder cancer. Urology 2001; 57: 617-21.
40. Luo Y, Knudson MJ. Mycobacterium bovis bacillus Calmette-Guérin-induced macrophage cytotoxicity against bladder cancer cells. Clin Dev Immunol 2010; 2010: 357591.
41. Naoe M, Ogawa Y, Takeshita K et al. Bacillus Calmette-Guérin-pulsed dendritic cells stimulate natural killer T cells and gamma delta T cells. Int J Urol 2007; 14: 532-8.
42. Fernandez-Gomez J, Solsona E, Unda M et al. Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: multivariate analysis of data from four randomized CUETO trials. Eur Urol 2008; 53: 992-1001.
43. Saint F, Patard JJ, Maille P et al. Prognostic value of a T helper 1 urinary cytokine response after intravesical bacillus Calmette-Guerin treatment for superficial bladder cancer. J Urol 2002; 167: 364-7.
44. Watanabe E, Matsuyama H, Matsuda K et al. Urinary interleukin-2 may predict clinical outcome of intravesical bacillus Calmette-Guérin immunotherapy for carcinoma in situ of the bladder. Cancer Immunol Immunother 2003; 52: 481-6.
45. Kumar A, Dubey D, Bansal P, Mandhani A, Naik S. Urinary interleukin-8 predicts the response of standard and low dose intravesical bacillus Calmette-Guerin (modified Danish 1331 strain) for superficial bladder cancer. J Urol 2002; 168: 2232-5.
46. Thalmann GN, Sermier A, Rentsch C, Möhrle K, Cecchini MG, Studer UE. Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin. J Urol 2000; 164: 2129-33.
47. de Reijke TM, De Boer EC, Kurth KH, Schamhart DH. Urinary interleukin-2 monitoring during prolonged bacillus Calmette-Guerin treatment: can it predict the optimal number of instillations? J Urol 1999; 161: 67-71.
48. Saint F, Kurth N, Maille P et al. Urinary IL-2 assay for monitoring intravesical bacillus Calmette-Guérin response of superficial bladder cancer during induction course and maintenance therapy. Int J Cancer 2003; 107: 434-40.
49. Zuiverloon TC, Nieuweboer AJ, Vékony H, Kirkels WJ, Bangma CH, Zwarthoff EC. Markers predicting response to bacillus Calmette-Guérin immunotherapy in high-risk bladder cancer patients: a systematic review. Eur Urol 2012; 61: 128-45.
50. Wei H, Kamat A, Chen M et al. Association of polymorphisms in oxidative stress genes with clinical outcomes for bladder cancer treated with Bacillus Calmette-Guérin. PLoS ONE 2012; 7: e38533.
51. Luo Y, Henning J, O'Donnell MA. Th1 cytokine-secreting recombinant Mycobacterium bovis bacillus Calmette-Guérin and prospective use in immunotherapy of bladder cancer. Clin Dev Immunol 2011; 2011: 728930.
52. Ozeki Y, Kaneda K, Fujiwara N, Morimoto M, Oka S, Yano I. In vivo induction of apoptosis in the thymus by administration of mycobacterial cord factor (trehalose 6, 6′-dimycolate). Infect Immun 1997; 65: 1793-9.
53. Yamagami H, Matsumoto T, Fujiwara N et al. Trehalose 6, 6′-dimycolate (cord factor) of Mycobacterium tuberculosis induces foreign-body- and hypersensitivity-type granulomas in mice. Infect Immun 2001; 69: 810-15.
54. Strohmeier GR, Fenton MJ. Roles of lipoarabinomannan in the pathogenesis of tuberculosis. Microbes Infect 1999; 9: 709-17.
55. Bendinger B, Rijnaarts HH, Altendorf K, Zehnder AJ. Physicochemical cell surface and adhesive properties of coryneform bacteria related to the presence and chain length of mycolic acids. Appl Environ Microbiol 1993; 59: 3973-7.
56. Khalil IA, Kogure K, Futaki S et al. Octaarginine-modified multifunctional envelope-type nanoparticles for gene delivery. Gene Ther 2007; 14: 682-9.
57. Kogure K, Moriguchi R, Sasaki K, Ueno M, Futaki S, Harashima H. Development of a non-viral multifunctional envelope-type nano device by a novel lipid film hydration method. J Control Release 2004; 98: 317-23.
58. Khalil IA, Kogure K, Futaki S, Harashima H. High density of octaarginine stimulates macropinocytosis leading to efficient intracellular trafficking for gene expression. J Biol Chem 2006; 281: 3544-51.
59. Moriguchi R, Kogure K, Akita H et al. A multifunctional envelope-type nano device for novel gene delivery of siRNA plasmids. Int J Pharm 2005; 301: 277-85.
60. Joraku A, Homhuan A, Kawai K et al. Immunoprotection against murine bladder carcinoma by octaarginine-modified liposomes incorporating cell wall of Mycobacterium bovis bacillus Calmette-Guérin. BJU Int 2009; 103: 686-93.
61. Miyazaki J, Kawai K, Kojima T et al. The liposome-incorporating cell wall skeleton of Mycobacterium bovis bacillus Calmette-Guérin can directly enhance the susceptibility of cancer cells to lymphokine-activated killer cells through up-regulation of natural-killer group 2, member D ligands. BJU Int 2011; 108: 1520-6.
62. Miyazaki J, Nishiyama H, Yano I et al. The therapeutic effects of R8-liposome-BCG-CWS on BBN-induced rat urinary bladder carcinoma. Anticancer Res 2011; 31: 2065-71.